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Methods: Urine was collected from 78 bladder-cancer patients
during follow-up, from 20 patients with benign urological disease,
and from 20 healthy volunteers. RNAwas isolated from exfoliated
cells in urine by use of an RNA purification kit, and real-time PCR
was performed with specific primers for the amplification of
CK20, a marker for TCC urothelium.
Findings: A strong correlation was found between tumour
grade and expression of CK20 in urine. All patients with grade
III and IV tumours showed positive CK20 expression in the exfo-
liated cells, with 100% sensitivity. The sensitivity for lower grades
was up to 83%. Out of 13 TCC patients, CK20 expression was
found in nine patients who were previously diagnosed by biopsy
and had a negative biopsy following treatment. These nine
patients were followed up for 6 months, and TCC recurred in four
patients.
Interpretation: Quantitative detection of CK20 in exfoliated cells
of urine is a simple and non-invasive method for monitoring and
follow-up of TCC in patients with bladder cancer. However, more
information is needed regarding CK20 expression in non-malig-
nant urological diseases to use it as amarker for routine screening.
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Background: Anthracycline-based neoadjuvant chemotherapy
kills cancer cells by inducing DNA double-strand breaks. In-
vitro studies have shown that DNA damage leads to localised
DNA methylation on CpG-rich sites found in promoter
regions. Promoter methylation of some tumour-suppressor
genes has been associated with poor prognosis. To determine
whether neoadjuvant chemotherapy induces promoter methyl-
ation, we evaluated the promoter regions of the SFRP1 and
CDH1 genes in locally advanced breast cancer, before and
after treatment.
Methods: Paired FFPE blocks of 61 patients with locally
advanced breast cancer before and after chemotherapy were col-
lected and confirmed by pathologists. Patients had standard fluo-
rouracil, doxorubicin (adriamycin), and cyclophosphamide (FAC)
chemotherapy for three cycles. In a subset of 12 patients, epige-
netic therapy (hydralazine and magnesium valproate) was added.
DNA isolation and bisulfite conversion were performed to evalu-
ate promoter methylation of SFRP1 and CDH1 genes using
methyl-specific PCR (MSP).
Findings: Using SFRP1 and CDH1 as surrogate markers, 13 of 41
(32%) and 18 of 48 (38%) patients showed induction of promoter
hypermethylation after chemotherapy (p = 0.052 and p = 0.012,
McNemar test). However, the rate of demethylation of both mark-
ers was 10%. To explore the reversibility of chemotherapy-
induced promoter hypermethylation, a subset of 12 patients were
treated with a combination of epigenetic therapy and chemother-
apy. Two of 12 patients (17%) showed hypermethylation and four
of 12 (33%) had an increased rate of promoter demethylation. The
dynamic status of promoter methylation is not associated with
hormone-receptor status, HER2 expression, age, or stage.
Interpretation: Neoadjuvant chemotherapy can induce pro-
moter methylation of tumour suppressor genes in a significant
proportion of patients, which may affect long-term clinical out-
come. This trend of promoter hypermethylation of tumour-sup-
pressor genes can be reversed using epigenetic therapy.
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Background: To determine the recommended dose and dose-
limiting toxicity (DLT) of epirubicin, oxaliplatin, and S-1 (EOS)
combination in patients with previously untreated advanced gas-
tric cancer (AGC).
Methods: Previously untreated patients with histologically pro-
ven metastatic or recurrent AGC and ECOG performance status 0–
2 were enrolled. A fixed dose of epirubicin (50 mg/m2) and oxalipl-
atin (130 mg/m2) was administered intravenously on day 1. The
dose of S-1 was escalated as follows: level 1, 30 mg/m2; level 2,
40 mg/m2; level 3, 45 mg/m2; level 4, 50 mg/m2. S-1 was adminis-
tered orally twice a day on days 1–14. Each cycle was repeated
every 21 days. DLTs were evaluated during the first two cycles
of treatment.
Findings: 19 patients were enrolled: 13 patients in the dose-
escalation phase and six patients in the extension at the recom-
mended dose. The median age was 53 years (range, 40–71 years).
At dose level 2, one DLToccured among six patients (grade 4 neu-
tropenia lasting more than 5 days), and at dose level 3, two DLTs
were observed among four patients (grade 3 diarrhoea and nau-
sea). Therefore, dose level 2 was determined to be the recom-
mended dose. Cumulative (all cycles) grade 3–4 toxicity included
neutropenia (58%), leucopenia (32%), thrombocytopenia (11%),
diarrhoea (11%), and nausea (5%). Of 13 patients with measurable
lesions, eight achieved a partial response and three had stable
disease, and the objective response rate was 62% (95% CI 36–
88%). Median progression-free survival was 6.5 months (4.7–8.2).
Interpretation The recommended dose of the EOS regimen in
patients with previously untreated AGC was epirubicin 50 mg/
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